DIAGNOS Inc.

ADK

CA2524423068

IT Services & Consulting

Market Closed - Toronto S.E. Other stock markets 03:59:47 2024-04-24 pm EDT			5-day change	1st Jan Change
0.295 ^CAD	-1.67%		-3.28%	-27.16%

Apr. 16	DIAGNOS Inc. to Expedite Application for Medical Device License to Health Canada and US FDA Related to its 4 New Analysis Modules, and is Planning ISO 27001 Certification	CI
Apr. 02	DIAGNOS Inc. Appoints Philippe Couillard to Its Board of Directors	CI

DIAGNOS Inc. announced that it has received CAD 0.85 million in funding

December 11, 2022

On December 12, 2022, DIAGNOS Inc. closed the transaction. The company issued 7 additional units for gross proceeds of CAD 350,000 in its final tranche. The company received CAD 850,000 in the transaction.

Latest news about DIAGNOS Inc.

DIAGNOS Inc. to Expedite Application for Medical Device License to Health Canada and US FDA Related to its 4 New Analysis Modules, and is Planning ISO 27001 Certification	Apr. 16	CI
DIAGNOS Inc. Appoints Philippe Couillard to Its Board of Directors	Apr. 02	CI
Diagnos Raises C$182,000 in the Final Tranche of a Private Placement of Share Units	Mar. 22	MT
DIAGNOS Inc. announced that it has received CAD 0.578 million in funding	Mar. 21	CI
Diagnos Announces Grant Of Stock Options	Mar. 04	MT
DIAGNOS Inc. Appoints Michael Braeuel to Board of Directors	Feb. 29	CI
DIAGNOS Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 28	CI
DIAGNOS Announces Closing Of First Tranche Of Private Placement	Feb. 27	MT
DIAGNOS Inc. announced that it expects to receive CAD 1.19244 million in funding	Feb. 26	CI
Diagnos Inc. Appoints Yves-Stéphane Couture as Chief Operating Officer	Jan. 16	CI
Diagnos Secures Exclusive Distribution Agreement for Canada with EssilorLuxottica	Dec. 11	MT
Diagnos Inc. Secures Exclusive Distribution Agreement for Canada with Essilorluxottica	Dec. 11	CI
DIAGNOS Inc. announced that it has received CAD 0.640051 million in funding	Dec. 03	CI
DIAGNOS Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 28	CI
DIAGNOS Inc. Announces Commencement of its Innovative Deployment in an Advanced Screening Program At Canada's Presented Specialist Care Provider in Diabetes and Endocrinology	23-10-05	CI
DIAGNOS Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-24	CI
DIAGNOS Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-07-13	CI
DIAGNOS Inc. Auditor Raises 'Going Concern' Doubt	23-07-12	CI
Diagnos Raises C$865,000 in Private Placement of Convertible Debentures and Warrants	23-05-18	MT
DIAGNOS Inc. announced that it has received CAD 0.865 million in funding	23-05-17	CI
Diagnos Announces Launch of "IRIS-ai powered by DIAGNOS"	23-05-17	MT
DIAGNOS Inc. and IRIS, The Visual Group Strengthens Partnership with the Launch of "IRIS-ai Powered by DIAGNOS"	23-05-17	CI
Diagnos and ETS Unveil Method to Adapt Deep Learning Algorithms	23-02-28	MT
DIAGNOS and ETS to Present Research on Mass Screening for Macular Edema at ARVO 2023	23-02-14	CI
Diagnos Gets OK For the Use of Diabetic Retinopathy Screening Technology in Quebec Hospitals	23-01-31	MT

Chart DIAGNOS Inc.

Duration

Period

More charts

Company Profile

DIAGNOS Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for modifying and developing of applications, such as Computer Assisted Retina Analysis (CARA). CARAâs image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. Its geographical areas include Canada, the United States, Saudi Arabia, Mexico, Costa Rica and Chile. The Companyâs subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.

Sector

IT Services & Consulting

Calendar

2024-06-05 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.295 CAD

Average target price

1.5 CAD

Spread / Average Target

+408.47%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other IT Services & Consulting

	1st Jan change	Capi.
DIAGNOS INC.	-27.16%	16.48M
ACCENTURE PLC	-10.65%	197B
TATA CONSULTANCY SERVICES LTD.	+1.21%	166B
IBM	+12.56%	169B
AUTOMATIC DATA PROCESSING, INC.	+5.85%	101B
RELX PLC	+6.27%	76.87B
CROWDSTRIKE HOLDINGS, INC.	+16.57%	71.98B
INFOSYS LIMITED	-6.99%	71.09B
SNOWFLAKE INC.	-22.12%	51.76B
HCL TECHNOLOGIES LIMITED	+2.07%	48.08B

Other IT Services & Consulting

DIAGNOS Inc.

Equities

ADK

CA2524423068

IT Services & Consulting

DIAGNOS Inc. announced that it has received CAD 0.85 million in funding

Latest news about DIAGNOS Inc.

Chart DIAGNOS Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other IT Services & Consulting